B-Cell Lymphoma

Our panel of experts discuss 3-year findings from the phase II ELARA study

CD19-directed CAR T-cell therapy led to persistent complete remission in 15 patients with three distinct autoantibody-dependent autoimmune diseases.

Scientists at The Institute of Cancer Research, London, have created a compound that destroys a protein involved in driving cancers, including B-cell lymphoma.

Under CEO Paul Stoffels, the Belgian pharma company is testing a device that manufactures personalized cancer therapies in hospitals, bringing down the price.

POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say

The award-winning actress opened up about her latest health news

Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease

BCMA-directed ciltacabtagene autoleucel led to responses in 98%

The 5-year results of the POLARIX study show a continued progression-free survival benefit for patients with diffuse large B-cell lymphoma who received pola-R-CHP.

"Full House" actor Dave Coulier who played Joey Gladstone reveals he has Stage 3 non-Hodgkin lymphoma. He's undergoing chemotherapy to treat his cancer.

Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets

Two European studies reported on a potentially strong predictive biomarker for marginal lymphoma in Sjögren disease and the effectiveness of systemic therapy vs localized treatment or watch and wait.

Post-treatment cases grow to 22 since products' initial approvals

Approach could allow for a response-adapted reduction of CHOP

Could one of your patients benefit from clinical trials now looking for patients with leukemia or lymphoma?

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

Epcoritamab is for patients who have received two or more lines of systemic therapy

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune or inflammatory disease.

Chemotherapy-free treatment options are giving hope to chronic lymphocytic leukemia patients.

The researchers' recently published study describes a way to re-activate apoptosis in mutated cells, which would amount to forcing cancer to self-destruct through a bioengineered, bonding molecule.